Abstract
This pilot study was designed to compare the levels of interleukin-8 (IL-8), a pro-inflammatory chemokine, in the cerebrospinal fluid (CSF) of patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), non-inflammatory polyneuropathy (PNP), and other non-inflammatory neurological diseases (functional syndrome or migraine). The results show elevated CSF IL-8 levels in GBS compared to the other groups (p < 0.05). IL-8 could be considered a potential biomarker to differentiate GBS from CIDP. This distinction could be relevant in terms of therapeutic decisions and functional prognosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- CSF:
-
cerebrospinal fluid
- IL-8:
-
interleukin-8
- GBS:
-
Guillain-Barre syndrome
- CIDP:
-
chronic inflammatory demyelinating polyneuropathy
- PNP:
-
polyneuropathy
- ENMG:
-
electroneuromyography
- IVIg:
-
intravenous immunoglobulin
- ROS:
-
reactive oxygen species
- AP-1:
-
activator protein 1
- HNPP:
-
hereditary neuropathy with pressure palsy
References
Alessandro L, Pastor Rueda JM, Wilken M, et al. Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. J Peripher Nerv Syst 2018; 23(3):154–8.
Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J. Med 2012; 14:2294–304.
van Doom PA, Ruts L, Jacobs BC. Clinical features, pathogenesis and treatment of Guillain-Barre syndrome. Lancet Neurol 2008; 7:939–50.
Ruts L, Drenthen J, Jacobs BC, Van Doom PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome. A. prospective study. Neurology 2010; 74:1680–6.
Hughes R. Guillain-Barre Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 1993; 341:586–90.
Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011; 7:507–11.
Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics 2017; 7:1543–88.
Sampson AP. The role of eosinophils and neutrophils in inflammation. Clinical and experimental allergy. Clin Exp Allergy 2000; 30(Suppl 1):22–7.
Press R, Pashenkov M, Jin JP, Link H. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Immunol 2003; 23:259–67.
Illes Z, Blaabjerg M. Cerebrospinal fluid findings in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathies. Handb Clin Neurol 2017; 146:125–38.
Stone J, Carson A, Sharpe M. Functional symptoms and signs in neurology: assessment and diagnosis. J. Neurol Neurosurg Psychiatry 2005; 76(Suppl 1):i2–12.
Wang Y, Sun S, Zhu J, Cui L, Zhang HL. Biomarkers of Guillain-Barre syndrome: some recent progress, more still to be explored. Mediators Inflamm 2015; 2015:564098.
Sainaghi PP, Collimedaglia L, Alciato F, et al. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barre syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 2010; 51:138–43.
Svahn J, Antoine JC, Camdessanche JP. Pathophysiology and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathies. Rev Neurol (Paris) 2014; 170:808–17.
Curtis AM, Bellet MM, Sassone-Corsi P, O’Neill LA. Circadian clock proteins and immunity. Immunity 2014; 40:178–86.
Ella K, Csepanyi-Komi R, Kaldi K. Circadian regulation of human peripheral neutrophils. Brain Behav Immun 2016; 57:209–21.
van Doom PA. Treatment of Guillain-Barre syndrome and CIDP. J Peripher Nerv Syst 2005; 10:113–27.
Hughes RA, Brassington R, Gunn AA, van Doom PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev 2016; 10:Cd001446.
Acknowledgements
The authors thank Christine Modoux for her skillful measurement of cytokines in CSF.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Breville, G., Lascano, A.M., Roux-Lombard, P. et al. IL-8 as a potential biomarker in Guillain-Barre Syndrome. Eur Cytokine Netw 30, 130–134 (2019). https://doi.org/10.1684/ecn.2019.0436
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ecn.2019.0436